Future clinical trials with pharmacological agents that target the 5-HT4R system, carefully considering treatment dose and duration, are needed to confirm whether directly targeting 5-HT4R can improve emotion processing biases in MDD. This evidence concerns the gene HTR4 and major depressive disorder.